IN THE NEWS
Dr. Jeffrey Fischer Co-Authors FDA LASIK Study on NIDEK EC-5000Dr. Jeffrey Fischer recently co-authored a FDA study, measuring the safety and effectiveness of the NIDEK EC-5000 excimer laser system's Customized Aspheric Treatment Zone(CATZ) for the treatment of myopia with and without astigmatism.
This CATZ LASIK treatment profile allows for a smoother transition between treated and untreated cornea. Another unique feature of this treatment is it is the only excimer laser capable of performing laser vision correction using a topography guided treatment. This individually customized LASIK treatment allows for better post operative vision, and also the reduced possiblility of glare.
In the study conducted by the United States Food and Drug Administration, Dr. Fischer and six other doctors across the country assessed the efficacy, predictability and safety of LASIK on patients. Results after surgery concluded that 89% of patients treated had 20/20 vision or better. In addition patients reported significantly fewer night driving, glare and halo complaints post operatively than pre operatively.
The outcome of the study reports that the corrective surgery surpassed all FDA criteria.
Dr. Tom Lenz Joins the Family Eye Center
Dr. Lenz grew up in Renville and graduated from Concordia College. He then earned his doctor of optometry from the Illinois College of Optometry, where he was awarded the Dr. Myrel A. Neumann Scholarship for clinical excellence. In addition to providing primary eye care, Dr. Lenz is our low vision specialist.Dr. Lenz practices at Family Eye Center's Willmar and Olivia offices.
NEW Selective Laser Procedure at Family Eye Center
Selective Laser Trabeculoplasty (SLT) is an exciting new glaucoma treatment that lowers eye pressure in a safe, effective, in office procedure. This procedure only takes a few minutes and is covered by most insurance companies. In some cases this revolutionary procedure eliminates or reduces the need for eye drops. In the past glaucoma surgeries have been either been ineffective or only used in severe cases. This low risk treatment option has changed the way glaucoma is being treated and in some cases is used as an initial treatment option before using any eye drops.
Family Eye Center welcomes new physicians.
| Dr. Mike Main and Dr. Carol Sheker-Main: | |
![]() |
|
State of the art technology at Family Eye Center
In pursuit of the latest technology available, Family Eye Center and Fischer Laser Eye Center use two of the most advanced diagnostic tools available. The Oculus Pentacam and the Nidek OPD Scan provide more diagnostic information than any other comparable instrumentation.
Think you’re a candidate for LASIK?
At Fischer Laser Eye Center we use the latest technology to help determine whether or not you are a candidate for LASIK. Using state of the art diagnostic equipment such as the Oculus Pentacam and Nidek OPD SCAN, we can analyze the cornea from front to back rule out any corneal problems or "red flags." Our comprehensive LASIK consultation takes 1-1.5 hours. During this exam we discuss which LASIK treatment is most appropriate for your individual situation. We do not believe in a one size fits all mentality. We consider prescription, eye health, age, occupation, hobbies and overall lifestyle to customize your LASIK experience. The decision to have LASIK is a major decision in your life. There is a wealth of information available in advertisements and the media about LASIK. Our goal is to educate you about LASIK in general, discuss realistic expectations for your individual situation, and provide you with enough information to allow you to determine whether or not LASIK is right for you.
STAAR Surgical's VISIAN ICL™ Receives FDA Approval MONROVIA, CA
-- December 23, 2005 -- STAAR Surgical Company reported that the U.S. Food and Drug Administration (FDA) has approved the Company's Myopic VISIAN ICL(TM) for use in the correction of myopia in adults.
Made of STAAR's proprietary, highly biocompatible Collamer(R) material, the ICL (Implantable Collamer Lens) is the only minimally invasive foldable lens of its kind approved for the U.S. commercial market.

